

A Robust Protocol for Pd(II)-catalyzed C-3 Arylation of (*1H*) Indazoles and Pyrazoles: Total Synthesis of Nigellidine Hydrobromide

Mengchun Ye¹, Andrew J. F. Edmunds², James A. Morris³, David Sale³, Yejia Zhang¹, and Jin-Quan Yu^{1*}

¹*Department of Chemistry, The Scripps Research Institute, 10550 N. Torrey Pines Rd., La Jolla, California 92037;* ²*Syngenta Crop Protection AG Schaffhauserstrasse, CH-4332 Stein, Switzerland;* ³*Syngenta Ltd., Jealott's Hill International Research Centre, Bracknell, Berkshire, RG42 6EY, U.K.*

SUPPORTING INFORMATION

Table of Contents

General Information.....	page	S-2
Experimental	pages	S-2 – S-16
1. General Procedure for Substrate Synthesis.....	pages	S-2 – S-5
2. General Procedure for C-3 Arylation.....	pages	S-5 – S-13
3. Total Synthesis of Nigellidine.....	pages	S-13 – S-16
References.....	pages	S-17


General Information:

Unless otherwise noted, all reactions were run under air and were heated on hot plates with oil baths calibrated to an external thermometer. Prior to starting experiments, the hot plate was turned on, and the oil bath was allowed to equilibrate to the desired temperature over 30 minutes. All materials were used as received from commercial sources without further purification and all reagents were handled in air. ^1H and ^{13}C NMR spectra were recorded on Varian-Inova and Bruker AV (400 MHz and 100 MHz, respectively) instrument internally referenced to SiMe_4 or chloroform signals. The following abbreviations (or combinations thereof) were used to explain multiplicities: s = singlet, d = doublet, t = triplet, q = quartet, and m = multiplet. High resolution mass spectra were recorded at the Center for Mass Spectrometry, The Scripps Research Institute.


Experimental:

1. General Procedure for Substrate Synthesis:


(1) General Procedure for 1-Me-, Bn-, and SEM-indazole¹:



To a suspended solution of NaH (6 mmol, 1.5 eq) in DMF (5 mL) and DMSO (2.5 mL), was added substituted indazole (4 mmol, 1.0 eq) in DMF (5 mL) at 0 °C under N_2 atmosphere. Then the reaction mixture was warmed to rt and stirred for 15 minutes. The solution was cooled back to 0 °C whereupon alkyl halide (6.4 mmol, 1.6 eq) was added dropwise to the stirred solution. Upon complete addition, the solution was stirred at rt overnight. The reaction was then quenched with saturated NH_4Cl and extracted with Et_2O . The combined organic phases were washed with brine, dried over anhydrous Na_2SO_4 , filtered, and concentrated in *vacuo*. The resulting residue was purified by silica gel column using hexane:ethyl acetate (4:1 to 1:1) as the eluent to give the corresponding protected 1H-indazole and 2H-indazole (the ratio is about 2:1 to 3:1).




1-Methyl-1H-indazole²: white solid, ^1H NMR (400 MHz, CDCl_3) δ 7.99 (s, 1H), 7.73 (d, J = 8.1 Hz, 1H), 7.39 (d, J = 3.6 Hz, 2H), 7.15 (dt, J = 7.9, 3.8 Hz, 1H), 4.07 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 139.77, 132.60, 126.10, 123.91, 120.96, 120.32, 108.80, 35.40.




2-Methyl-2H-indazole³: white solid, ^1H NMR (400 MHz, CDCl_3) δ 7.79 (s, 1H), 7.69 (d, J = 8.7 Hz, 1H), 7.61 (d, J = 8.4 Hz, 1H), 7.26 (t, J = 8.0 Hz, 1H), 7.05 (t, J = 8.0 Hz, 1H), 4.13 (s,


3H); ^{13}C NMR (100 MHz, CDCl_3) δ 148.87, 125.67, 123.36, 121.92, 121.43, 119.81, 117.02, 40.08.




1-Benzyl-1H-indazole⁴: white solid, ^1H NMR (400 MHz, CDCl_3) δ 8.04 (s, 1H), 7.73 (d, $J = 8.1$ Hz, 1H), 7.36 – 7.20 (m, 5H), 7.18 (d, $J = 6.7$ Hz, 2H), 7.14 – 7.10 (m, 1H), 5.58 (s, 2H); ^{13}C NMR (100 MHz, CDCl_3) δ 139.49, 136.84, 133.32, 128.65, 127.67, 127.10, 126.32, 124.31, 121.09, 120.58, 109.23, 52.90.




1-((2-(Trimethylsilyl)ethoxy)methyl)-1H-indazole⁵: colorless oil, ^1H NMR (400 MHz, CDCl_3) δ 8.02 (s, 1H), 7.74 (d, $J = 8.1$ Hz, 1H), 7.58 (d, $J = 8.4$ Hz, 1H), 7.42 (t, $J = 7.7$ Hz, 1H), 7.19 (t, $J = 7.5$ Hz, 1H), 5.75 (s, 2H), 3.55 (t, $J = 8.0$ Hz, 2H), 0.89 (t, $J = 8.0$ Hz, 2H), -0.07 (s, 9H); ^{13}C NMR (100 MHz, CDCl_3) δ 139.69, 133.98, 126.68, 124.74, 121.22, 120.99, 109.93, 109.61, 77.61, 66.31, 17.70, -1.53.




4-Chloro-1-methyl-1H-indazole⁶: yellow oil, ^1H NMR (400 MHz, CDCl_3) δ 8.04 (s, 1H), 7.29 – 7.24 (m, 2H), 7.12 – 7.07 (m, 1H), 4.05 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 140.70, 131.33, 126.70, 126.51, 123.18, 120.01, 107.47, 35.78




Methyl 1-methyl-1H-indazole-5-carboxylate: brown solid, ^1H NMR (400 MHz, CDCl_3) δ 8.50 (s, 1H), 8.07 (s, 1H), 8.06 (d, $J = 8.0$ Hz, 1H), 7.39 (d, $J = 8.0$ Hz, 1H), 4.09 (s, 3H), 3.94 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 167.28, 141.53, 134.47, 127.04, 124.57, 123.63, 122.77, 108.61, 52.05, 35.68; **HRMS** (ESI-TOF) m/z Calcd for $\text{C}_{10}\text{H}_{11}\text{N}_2\text{O}_2$ $[\text{M}+\text{H}]^+$ 191.0815, found 191.0820.



6-Fluoro-1-methyl-1H-indazole: white solid, ^1H NMR (400 MHz, CDCl_3) δ 7.93 (s, 1H), 7.64 (dd, $J = 8.8, 5.1$ Hz, 1H), 7.00 (d, $J = 9.2$ Hz, 1H), 6.90 (td, $J = 9.0, 2.1$ Hz, 1H), 4.00 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 162.06 (d, $J = 243$ Hz), 140.11 (d, $J = 12.0$ Hz), 132.91, 122.34 (d, $J = 11.0$ Hz), 120.77, 110.34 (d, $J = 25.0$ Hz), 94.50 (d, $J = 26.0$ Hz), 35.49; **HRMS** (ESI-TOF) m/z Calcd for $\text{C}_8\text{H}_8\text{FN}_2$ $[\text{M}+\text{H}]^+$ 151.0666, found 151.0668.



7-Fluoro-1-methyl-1H-indazole: yellow oil, $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.94 (d, $J = 2.3$ Hz, 1H), 7.46 – 6.91 (m, 1H), 7.06 – 6.91 (m, 2H), 4.23 (s, 3H); $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 148.51(d, $J = 246$ Hz), 133.03 (d, $J = 1.0$ Hz), 129.37 (d, $J = 12.0$ Hz), 127.98 (d, $J = 4.0$ Hz), 120.78 (d, $J = 5.0$ Hz), 116.61 (d, $J = 4.0$ Hz), 110.58 (d, $J = 17.0$ Hz), 38.11 (d, $J = 4.0$ Hz); **HRMS** (ESI-TOF) m/z Calcd for $\text{C}_8\text{H}_8\text{FN}_2$ $[\text{M}+\text{H}]^+$ 151.0666, found 151.0665.




6-Chloro-1-methyl-1H-pyrazolo[3,4-b]pyridine: yellow solid, $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 8.02 (d, $J = 8.0$ Hz, 1H), 8.01 (s, 1H), 7.16 (d, $J = 8.0$ Hz, 1H), 4.17 (s, 3H); $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 150.55, 149.61, 132.14, 132.04, 117.31, 114.08, 34.18; **HRMS** (ESI-TOF) m/z Calcd for $\text{C}_7\text{H}_7\text{ClN}_3$ $[\text{M}+\text{H}]^+$ 168.0328, found 168.0330.


(2) General Procedure for 1-THP-indazole⁷:



To a solution of substituted indazole (10 mmol, 1.0 eq) in DCM (40 mL), was added *p*-toluenesulfonic acid (571 mg, 3 mmol, 0.3 eq), and dihydropyran (DHP, 30 mmol, 3.0 eq). The solution was then stirred at rt until TLC showed a complete conversion of starting material. The solution was further diluted with DCM, washed with saturated NaHCO_3 . The separated organic phase was washed with brine, dried over anhydrous Na_2SO_4 , filtered, and concentrated *in vacuo*. The resulting residue was purified by silica gel column using hexane:ethyl acetate (6:1) as the eluent to give the sole 1-THP-1H-indazole.




1-(Tetrahydro-2H-pyran-2-yl)-1H-indazole⁷: colorless oil, $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 8.04 (s, 1H), 7.73 (d, $J = 8.1$ Hz, 1H), 7.60 (d, $J = 8.5$ Hz, 1H), 7.39 (t, $J = 8.0$ Hz, 1H), 7.17 (t, $J = 8.0$ Hz, 1H), 5.73 (dd, $J = 9.5, 2.7$ Hz, 1H), 4.06-4.01 (m, 1H), 3.78 – 3.72 (m, 1H), 2.65 – 2.55 (m, 1H), 2.18 – 2.06 (m, 2H), 1.79 – 1.63 (m, 3H); $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 139.42, 133.86, 126.42, 124.62, 121.11, 120.95, 109.90, 85.18, 67.43, 29.36, 25.07, 22.60.




4-Methoxy-6-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole 7: white solid, $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 8.02 (s, 1H), 6.94 (s, 1H), 6.32 (s, 1H), 5.63 (dd, $J = 9.5, 2.7$ Hz, 1H), 4.07

– 4.01 (m, 1H), 3.93 (s, 3H), 3.79 – 3.68 (m, 1H), 2.61 – 2.52 (m, 1H), 2.47 (s, 3H), 2.22 – 2.10 (m, 1H), 2.10 – 1.99 (m, 1H), 1.81 – 1.57 (m, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 153.18, 141.71, 138.47, 131.60, 114.76, 102.37, 102.25, 85.16, 67.49, 55.27, 29.35, 25.11, 22.70, 22.47; HRMS (ESI-TOF) m/z Calcd for $\text{C}_{14}\text{H}_{19}\text{N}_2\text{O}_2$ $[\text{M}+\text{H}]^+$ 247.1441, found 247.1450.


(3) General Procedure for Pyrazole Synthesis^{8,9}:




To a 35 mL sealed tube, were added N,N-dimethylformamide dimethyl acetal (DMFDMA) (1.0 mL, 7.5 mmol, 1.5 eq), and corresponding ketone (5 mmol, 1.0 eq) under N_2 atmosphere. The tube was capped and stirred at 130 °C overnight. The reaction mixture was cooled to rt and evaporated in *vacuo*. The residue was diluted with MeOH (13 mL) and transferred to a 50 mL flask, then HOAc (3.0 mL), H_2O (26 mL) and PhNHNH_2 (0.74 mL, 7.5 mmol) were added. The resulting mixture was heated to reflux overnight. After cooling, the mixture was evaporated to half volume in *vacuo*, and H_2O (20 mL) was added. The solution was extracted with DCM and the combined organic phases were washed with brine, dried over anhydrous Na_2SO_4 , filtered, and concentrated in *vacuo*. The resulting residue was purified by silica gel column using hexane:ethyl acetate (10:1) as the eluent to give the product.



1-Phenyl-4,5,6,7-tetrahydro-1H-indazole¹⁰: brown oil, ^1H NMR (400 MHz, CDCl_3) δ 7.54 – 7.38 (m, 5H), 7.33 – 7.27 (m, 1H), 2.74 – 2.71 (m, 2H), 2.64 – 2.51 (m, 2H), 1.82– 1.77 (m, 4H); ^{13}C NMR (100 MHz, CDCl_3) δ 140.04, 138.73, 138.10, 128.94, 126.49, 122.92, 117.66, 23.62, 23.10, 22.73, 20.67.




4-Methyl-1,5-diphenyl-1H-pyrazole¹¹: white solid, ^1H NMR (400 MHz, CDCl_3) δ 7.63 (s, 1H), 7.41 – 7.32 (m, 3H), 7.32 – 7.16 (m, 7H), 2.15 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 141.12, 140.27, 139.78, 130.56, 129.79, 128.64, 128.39, 127.94, 126.71, 124.59, 116.35, 9.17.




1,4,5-Triphenyl-1H-pyrazole¹²: white solid, ¹H NMR (400 MHz, CDCl₃) δ 7.91 (s, 1H), 7.35 – 7.18 (m, 13H), 7.15 (dt, *J* = 6.6, 1.7 Hz, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 139.95, 139.75, 139.20, 132.78, 130.44, 130.22, 128.69, 128.59, 128.44, 128.41, 127.96, 127.19, 126.37, 125.16, 122.42.


2. General Procedure for C-3 Arylation




To a 35 mL sealed tube, were added Pd(OAc)₂ (5.6 mg, 0.025 mmol), 1,10-phenanthroline (4.5 mg, 0.025 mmol), Cs₂CO₃ (82 mg, 0.25 mmol), aryl halide (0.25 mmol), indazole derivative (0.25 mmol), and toluene (1 mL). The tube was capped and stirred at 160 °C for 48-72 h. The reaction mixture was cooled to room temperature and diluted with EtOAc, filtered through a short pad of Celite, washed with EtOAc, and concentrated in *vacuo*. The resulting residue was purified by PTLC using hexanes:EtOAc (10:1 to 6:1, depending on different substrates) as the eluent.




1-Methyl-3-phenyl-1H-indazole¹³: colorless oil, ¹H NMR (400 MHz, CDCl₃) δ 8.04 (dd, *J* = 8.2, 0.9 Hz, 1H), 7.99 (d, *J* = 7.6 Hz, 2H), 7.52 (t, *J* = 7.6 Hz, 2H), 7.47 – 7.37 (m, 3H), 7.25 – 7.20 (m, 1H), 4.13 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 143.65, 141.38, 133.65, 128.75, 127.75, 127.32, 126.20, 121.56, 121.29, 120.85, 109.14, 35.48.




3-([1,1'-Biphenyl]-2-yl)-1-methyl-1H-indazole: white solid, ¹H NMR (400 MHz, CDCl₃) δ 8.02 (dd, *J* = 7.3, 2.0 Hz, 1H), 7.98 – 7.94 (m, 2H), 7.56 – 7.45 (m, 8H), 7.44 – 7.39 (m, 1H), 7.28 – 7.21 (m, 1H), 3.68 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 143.86, 139.29, 138.77, 133.54, 129.89, 128.79, 128.14, 128.04, 127.85, 127.75, 127.61, 126.20, 122.66, 120.82, 120.42, 39.23; HRMS (ESI-TOF) *m/z* Calcd for C₂₀H₁₇N₂ [M+H]⁺ 285.1386, found 285.1390.




1-Methyl-3-(p-tolyl)-1H-indazole: colorless oil, $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 8.02 (d, $J = 8.2$ Hz, 1H), 7.88 (d, $J = 8.1$ Hz, 2H), 7.45 – 7.39 (m, 2H), 7.33 (dd, $J = 7.9, 0.7$ Hz, 2H), 7.23 – 7.19 (m, 1H), 4.12 (s, 3H), 2.44 (s, 3H); $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 143.74, 141.36, 137.54, 130.78, 129.46, 127.21, 126.15, 121.56, 121.37, 120.69, 109.08, 35.44, 21.29; **HRMS** (ESI-TOF) m/z Calcd for $\text{C}_{15}\text{H}_{15}\text{N}_2$ $[\text{M}+\text{H}]^+$ 223.1230, found 223.1239.




1-Methyl-3-(m-tolyl)-1H-indazole: colorless oil, $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 8.03 (d, $J = 8.2$ Hz, 1H), 7.80 (s, 1H), 7.77 (d, $J = 7.6$ Hz, 1H), 7.46 – 7.38 (m, 3H), 7.24 – 7.20 (m, 1H), 4.13 (s, 3H), 2.47 (s, 3H); $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 143.83, 141.37, 138.43, 133.52, 128.64, 128.58, 127.95, 126.20, 124.50, 121.61, 121.39, 120.78, 109.12, 35.48, 21.52; **HRMS** (ESI-TOF) m/z Calcd for $\text{C}_{15}\text{H}_{15}\text{N}_2$ $[\text{M}+\text{H}]^+$ 223.1230, found 223.1238.




1-Methyl-3-(o-tolyl)-1H-indazole: colorless oil, $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.66 (d, $J = 8.2$ Hz, 1H), 7.56 – 7.51 (m, 1H), 7.46 – 7.40 (m, 2H), 7.38 – 7.29 (m, 3H), 7.19 – 7.15 (m, 1H), 4.15 (s, 3H), 2.42 (s, 3H); $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 144.44, 140.61, 137.15, 132.35, 130.64, 130.47, 128.03, 126.13, 125.61, 122.97, 121.37, 120.42, 108.94, 35.46, 20.50; **HRMS** (ESI-TOF) m/z Calcd for $\text{C}_{15}\text{H}_{15}\text{N}_2$ $[\text{M}+\text{H}]^+$ 223.1230, found 223.1237.




3-(4-Methoxyphenyl)-1-methyl-1H-indazole¹³: colorless oil, $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.99 (d, $J = 8.2$ Hz, 1H), 7.93 – 7.87 (m, 2H), 7.45 – 7.37 (m, 2H), 7.22 – 7.18 (m, 1H), 7.08 – 7.02 (m, 2H), 4.11 (s, 3H), 3.88 (s, 3H); $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 159.37, 143.54, 141.35, 128.53, 126.32, 126.15, 121.46, 121.31, 120.61, 114.21, 109.06, 55.30, 35.40.




1-Methyl-3-(4-(methylthio)phenyl)-1H-indazole: colorless oil, $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.99 (dd, $J = 8.2, 1.0$ Hz, 1H), 7.90 (d, $J = 7.9$ Hz, 2H), 7.46 – 7.36 (m, 4H), 7.24 – 7.18 (m, 1H), 4.12 (s, 3H), 2.54 (s, 3H); $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 143.11, 141.39, 138.00, 130.55, 127.60, 126.83, 126.23, 121.48, 121.20, 120.86, 109.18, 35.49, 15.83; **HRMS** (ESI-TOF) m/z Calcd for $\text{C}_{15}\text{H}_{15}\text{N}_2\text{S}$ $[\text{M}+\text{H}]^+$ 255.0950, found 255.0958.



3-(4-Fluorophenyl)-1-methyl-1H-indazole: colorless oil, $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.96 (d, $J = 8.3$ Hz, 1H), 7.94 – 7.89 (m, 2H), 7.47 – 7.40 (m, 2H), 7.25 – 7.16 (m, 3H), 4.13 (s, 3H); $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 162.62 (d, $J = 246$ Hz), 142.09 (d, $J = 146$ Hz), 129.56 (d, $J = 3.0$ Hz), 129.07, 128.99, 126.54, 121.34, 121.11 (d, $J = 1.0$ Hz), 115.89, 115.68, 109.26, 35.47; **HRMS** (ESI-TOF) m/z Calcd for $\text{C}_{14}\text{H}_{12}\text{FN}_2$ $[\text{M}+\text{H}]^+$ 227.0979, found 227.0979.




3-(4-Chlorophenyl)-1-methyl-1H-indazole: colorless oil, $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.97 (dt, $J = 8.2, 1.0$ Hz, 1H), 7.93 – 7.88 (m, 2H), 7.50 – 7.45 (m, 2H), 7.45 – 7.41 (m, 2H), 7.25 – 7.21 (m, 1H), 4.12 (s, 3H); $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 142.46, 141.42, 133.57, 132.19, 128.95, 128.46, 126.36, 121.40, 121.13, 121.01, 109.29, 35.56; **HRMS** (ESI-TOF) m/z Calcd for $\text{C}_{14}\text{H}_{12}\text{ClN}_2$ $[\text{M}+\text{H}]^+$ 243.0683, found 243.0683.




1-Methyl-3-(4-(trifluoromethyl)phenyl)-1H-indazole: colorless oil, $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 8.09 (d, $J = 7.8$ Hz, 2H), 8.01 (d, $J = 8.3$ Hz, 1H), 7.75 (d, $J = 8.5$ Hz, 2H), 7.49 – 7.42 (m, 2H), 7.28 – 7.24 (m, 1H), 4.14 (s, 3H); $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 142.02, 141.48, 137.24 (q, $J = 2.0$ Hz), 129.47 (q, $J = 32.0$ Hz), 127.29, 126.46, 125.68 (d, $J = 4.0$ Hz), 122.92,


121.51, 121.47, 120.88, 109.43, 35.64; **HRMS** (ESI-TOF) m/z Calcd for $C_{15}H_{12}F_3N_2$ $[M+H]^+$ 277.0947, found 277.0952.




1-Methyl-3-(3-(trifluoromethyl)phenyl)-1H-indazole: colorless oil, 1H NMR (400 MHz, $CDCl_3$) δ 8.26 (s, 1H), 8.16 (d, $J = 7.3$ Hz, 1H), 8.00 (d, $J = 8.2$ Hz, 1H), 7.68 – 7.58 (m, 2H), 7.46 – 7.44 (m, 2H), 7.29 – 7.23 (m, 1H), 4.14 (s, 3H); ^{13}C NMR (100 MHz, $CDCl_3$) δ 142.06, 141.47, 134.55, 131.19 (q, $J = 32.0$ Hz), 129.21, 126.46, 125.54, 124.31 (q, $J = 4.0$ Hz), 124.00 (q, $J = 4.0$ Hz), 122.83, 121.41, 121.39, 120.81, 109.40, 35.62; **HRMS** (ESI-TOF) m/z Calcd for $C_{15}H_{12}F_3N_2$ $[M+H]^+$ 277.0947, found 277.0952.



1-Methyl-3-(2-(trifluoromethyl)phenyl)-1H-indazole: colorless oil, 1H NMR (400 MHz, $CDCl_3$) δ 7.87 – 7.83 (m, 1H), 7.67 – 7.53 (m, 4H), 7.47 – 7.40 (m, 2H), 7.18 – 7.14 (m, 1H), 4.14 (s, 3H); ^{13}C NMR (100 MHz, $CDCl_3$) δ 142.10, 140.42, 132.74, 131.84 (q, $J = 2.0$ Hz), 131.37, 129.91 (q, $J = 31.0$ Hz), 128.42, 126.60 (q, $J = 4.0$ Hz), 126.34, 125.30, 123.38, 120.82, 120.73, 108.92, 35.59; **HRMS** (ESI-TOF) m/z Calcd for $C_{15}H_{12}F_3N_2$ $[M+H]^+$ 277.0947, found 277.0957.




4-(1-Methyl-1H-indazol-3-yl)benzonitrile¹³: colorless oil, 1H NMR (400 MHz, $CDCl_3$) δ 8.09 (d, $J = 8.3$ Hz, 2H), 7.99 (d, $J = 8.3$ Hz, 1H), 7.75 (d, $J = 8.2$ Hz, 2H), 7.50 – 7.42 (m, 2H), 7.29 – 7.25 (m, 1H), 4.15 (s, 3H); ^{13}C NMR (100 MHz, $CDCl_3$) δ 141.52, 141.35, 138.25, 132.53, 127.37, 126.57, 121.78, 121.44, 120.71, 119.01, 110.83, 109.58, 35.76.




Ethyl 4-(1-methyl-1H-indazol-3-yl)benzoate: colorless oil, 1H NMR (400 MHz, $CDCl_3$) δ 8.20 – 8.14 (m, 2H), 8.08 – 8.03 (m, 2H), 8.02 (dt, $J = 8.3, 0.9$ Hz, 1H), 7.47 – 7.39 (m, 2H), 7.29 – 7.18 (m, 1H), 4.41 (q, $J = 7.1$ Hz, 2H), 4.13 (s, 3H), 1.43 (t, $J = 7.2$ Hz, 3H); ^{13}C NMR (100


MHz, CDCl₃) δ 166.45, 142.36, 141.43, 138.02, 130.00, 129.36, 126.84, 126.37, 121.58, 121.39, 121.04, 109.35, 60.92, 35.62, 14.32; **HRMS** (ESI-TOF) m/z Calcd for C₁₇H₁₇N₂O₂ [M+H]⁺ 281.1284, found 281.1290.




1-Methyl-3-(pyridin-3-yl)-1H-indazole¹³: colorless oil, **¹H NMR** (400 MHz, CDCl₃) δ 9.24 (dd, $J = 2.3, 0.9$ Hz, 1H), 8.64 (dd, $J = 4.8, 1.7$ Hz, 1H), 8.26 (ddd, $J = 7.9, 2.3, 1.7$ Hz, 1H), 7.99 (dt, $J = 8.3, 1.0$ Hz, 1H), 7.50 – 7.39 (m, 3H), 7.30 – 7.22 (m, 1H), 4.15 (s, 3H); **¹³C NMR** (100 MHz, CDCl₃) δ 148.70, 148.26, 141.34, 140.45, 134.27, 129.72, 126.47, 123.63, 121.41, 120.74, 109.36, 35.61.



1-Methyl-3-(pyrimidin-5-yl)-1H-indazole: colorless oil, **¹H NMR** (400 MHz, CDCl₃) δ 9.32 (s, 2H), 9.21 (s, 1H), 7.94 (d, $J = 8.3$ Hz, 1H), 7.52 – 7.42 (m, 2H), 7.31 – 7.25 (m, 1H), 4.15 (s, 3H); **¹³C NMR** (100 MHz, CDCl₃) δ 157.43, 154.66, 141.37, 137.20, 128.07, 126.79, 122.00, 121.45, 120.29, 109.66, 35.83; **HRMS** (ESI-TOF) m/z Calcd for C₁₂H₁₁N₄ [M+H]⁺ 211.0978, found 211.0986.




3-(1-Methyl-1H-indazol-3-yl)quinoline: colorless oil, **¹H NMR** (400 MHz, CDCl₃) δ 9.58 (d, $J = 2.2$ Hz, 1H), 8.66 (s, 1H), 8.16 (d, $J = 8.5$ Hz, 1H), 8.08 (d, $J = 8.2$ Hz, 1H), 7.91 (d, $J = 8.6$ Hz, 1H), 7.77 – 7.67 (m, 1H), 7.62 – 7.55 (m, 1H), 7.47 – 7.45 (m, 2H), 7.31 – 7.24 (m, 1H), 4.17 (s, 3H); **¹³C NMR** (100 MHz, CDCl₃) δ 149.81, 147.44, 141.42, 140.61, 132.96, 129.34, 129.32, 128.04, 128.00, 126.97, 126.94, 126.55, 121.74, 121.53, 120.83, 109.46, 35.70; **HRMS** (ESI-TOF) m/z Calcd for C₁₇H₁₄N₃ [M+H]⁺ 260.1182, found 260.1185.




1-Benzyl-3-phenyl-1H-indazole¹³: colorless oil, **¹H NMR** (400 MHz, CDCl₃) δ 8.04 – 8.01 (m, 1H), 8.01 – 7.97 (m, 2H), 7.54 – 7.46 (m, 2H), 7.42 – 7.35 (m, 1H), 7.35 – 7.31 (m, 2H), 7.31 – 7.21 (m, 5H), 7.18 (dt, $J = 8.0, 3.9$ Hz, 1H), 5.64 (s, 2H); **¹³C NMR** (100 MHz, CDCl₃) δ 144.13,


141.03, 136.84, 133.63, 128.76, 128.65, 127.85, 127.65, 127.49, 127.09, 126.33, 122.06, 121.38, 121.06, 109.60, 53.03.




Ethyl 4-(1-benzyl-1H-indazol-3-yl)benzoate (Drug YD-3): colorless oil, ¹H NMR (400 MHz, CDCl₃) δ 8.20 – 8.14 (m, 2H), 8.12 – 8.06 (m, 2H), 8.03 (d, *J* = 8.3 Hz, 1H), 7.38 – 7.32 (m, 2H), 7.32 – 7.19 (m, 6H), 5.65 (s, 2H), 4.41 (q, *J* = 7.1 Hz, 2H), 1.42 (t, *J* = 7.1 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 166.46, 142.87, 141.08, 138.02, 136.53, 130.00, 129.46, 128.69, 127.76, 127.09, 127.03, 126.50, 122.07, 121.57, 121.14, 109.80, 60.93, 53.17, 14.33; **HRMS** (ESI-TOF) *m/z* Calcd for C₂₃H₂₁N₂O₂ [M+H]⁺ 357.1597, found 357.1581.




3-Phenyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indazole: colorless oil, ¹H NMR (400 MHz, CDCl₃) δ 8.07 (dt, *J* = 8.1, 1.0 Hz, 1H), 8.04 – 7.99 (m, 2H), 7.66 (dt, *J* = 8.5, 0.9 Hz, 1H), 7.59 – 7.52 (m, 2H), 7.52 – 7.42 (m, 2H), 7.33 – 7.25 (m, 1H), 5.84 (s, 2H), 3.77 – 3.59 (m, 2H), 1.06 – 0.89 (m, 2H), -0.01 (s, 9H); ¹³C NMR (100 MHz, CDCl₃) δ 144.81, 141.25, 133.37, 128.76, 128.07, 127.58, 126.69, 122.57, 121.64, 121.31, 109.92, 77.72, 66.40, 17.73, -1.47; **HRMS** (ESI-TOF) *m/z* Calcd for C₁₉H₂₅N₂OSi [M+H]⁺ 325.1731, found 325.1740.




3-Phenyl-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole: colorless oil, ¹H NMR (400 MHz, CDCl₃) δ 8.06 – 7.97 (m, 3H), 7.69 – 7.62 (m, 1H), 7.53 – 7.49 (m, 2H), 7.47 – 7.37 (m, 2H), 7.28 – 7.20 (m, 1H), 5.80 (dd, *J* = 9.3, 2.8 Hz, 1H), 4.15 – 4.04 (m, 1H), 3.81 – 3.75 (m, 1H), 2.72 – 2.67 (m, 1H), 2.31 – 2.07 (m, 2H), 1.86 – 1.60 (m, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 144.52, 140.92, 133.57, 128.65, 127.91, 127.65, 126.41, 122.50, 121.54, 121.28, 110.37, 85.52, 67.43, 29.36, 25.13, 22.60; **HRMS** (ESI-TOF) *m/z* Calcd for C₁₈H₁₉N₂O [M+H]⁺ 279.1492, found 279.1504.




4-Chloro-1-methyl-3-phenyl-1H-indazole: colorless oil, $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.76 – 7.71 (m, 2H), 7.51 – 7.44 (m, 3H), 7.35 (s, 1H), 7.34 (d, $J = 3.0$ Hz, 1H), 7.18 (dd, $J = 5.6, 2.6$ Hz, 1H), 4.14 (s, 3H); $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 144.72, 142.27, 133.00, 130.56, 128.04, 127.64, 127.28, 126.82, 121.52, 119.59, 107.81, 35.76; **HRMS** (ESI-TOF) m/z Calcd for $\text{C}_{14}\text{H}_{12}\text{ClN}_2$ $[\text{M}+\text{H}]^+$ 243.0683, found 243.0685.




Methyl 1-methyl-3-phenyl-1H-indazole-5-carboxylate: colorless oil, $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 8.75 (dd, $J = 1.5, 0.8$ Hz, 1H), 8.09 (dd, $J = 8.9, 1.5$ Hz, 1H), 8.00 – 7.93 (m, 2H), 7.53 (ddt, $J = 8.8, 7.0, 0.8$ Hz, 2H), 7.46 – 7.42 (m, 1H), 7.39 (dd, $J = 8.8, 0.8$ Hz, 1H), 4.12 (s, 3H), 3.96 (s, 3H); $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 167.26, 145.51, 143.03, 132.75, 128.88, 128.30, 127.48, 127.09, 124.84, 123.07, 121.30, 108.86, 52.07, 35.67; **HRMS** (ESI-TOF) m/z Calcd for $\text{C}_{16}\text{H}_{15}\text{N}_2\text{O}_2$ $[\text{M}+\text{H}]^+$ 267.1128, found 267.1129.




6-Fluoro-1-methyl-3-phenyl-1H-indazole: colorless oil, $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.96 – 7.89 (m, 3H), 7.53 – 7.50 (m, 2H), 7.44 – 7.38 (m, 1H), 7.04 (dd, $J = 9.1, 2.2$ Hz, 1H), 6.97 (dt, $J = 9.0, 2.2$ Hz, 1H), 4.06 (s, 3H); $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 162.11 (d, $J = 244$ Hz), 144.06, 141.76 (d, $J = 12.0$ Hz), 133.11, 128.82, 128.06, 127.33, 122.79 (d, $J = 10.9$ Hz), 118.51, 110.71 (d, $J = 25.7$ Hz), 94.77 (d, $J = 25.9$ Hz), 35.57; **HRMS** (ESI-TOF) m/z Calcd for $\text{C}_{14}\text{H}_{12}\text{FN}_2$ $[\text{M}+\text{H}]^+$ 227.0979, found 227.0988.




7-Fluoro-1-methyl-3-phenyl-1H-indazole: colorless oil, $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.97 – 7.90 (m, 2H), 7.78 – 7.72 (m, 1H), 7.55 – 7.47 (m, 2H), 7.45 – 7.38 (m, 1H), 7.12 – 7.02 (m, 2H), 4.31 (d, $J = 1.1$ Hz, 3H); $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 148.59 (d, $J = 246$ Hz), 144.34 (d, $J = 1.5$ Hz), 133.07, 130.95 (d, $J = 12.4$ Hz), 128.80, 128.05, 127.42, 125.63 (d, $J = 4.2$ Hz), 121.25 (d, $J = 5.44$ Hz), 117.00 (d, $J = 4.3$ Hz), 110.77 (d, $J = 16.9$ Hz), 38.31 (d, $J = 4.5$ Hz); **HRMS** (ESI-TOF) m/z Calcd for $\text{C}_{14}\text{H}_{12}\text{FN}_2$ $[\text{M}+\text{H}]^+$ 227.0979, found 227.0990.




6-Chloro-1-methyl-3-phenyl-1H-pyrazolo[3,4-b]pyridine: colorless oil, $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 8.30 (d, $J = 8.0$ Hz, 1H), 7.96 – 7.94 (m, 2H), 7.56 – 7.52 (m, 2H), 7.48 – 7.43 (m, 1H), 7.21 (d, $J = 8.0$ Hz, 1H), 4.21 (s, 3H); $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 150.51, 150.34, 143.00, 132.68, 132.11, 128.75, 128.60, 126.73, 117.35, 111.89, 33.55; **HRMS** (ESI-TOF) m/z Calcd for $\text{C}_{13}\text{H}_{11}\text{ClN}_3$ $[\text{M}+\text{H}]^+$ 244.0642, found 244.0647.




1,3-Diphenyl-4,5,6,7-tetrahydro-1H-indazole: yellow oil, $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.95 – 7.78 (m, 2H), 7.62 – 7.53 (m, 2H), 7.48 – 7.40 (m, 4H), 7.34 – 7.30 (m, 2H), 2.93 – 2.70 (m, 4H), 1.87 – 1.84 (m, 4H); $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 149.04, 140.02, 139.67, 134.10, 129.02, 128.40, 127.31, 126.92, 126.69, 123.39, 115.51, 23.94, 23.10, 22.75, 22.56; **HRMS** (ESI-TOF) m/z Calcd for $\text{C}_{19}\text{H}_{19}\text{N}_2$ $[\text{M}+\text{H}]^+$ 275.1543, found 275.1542.



4-Methyl-1,3,5-triphenyl-1H-pyrazole: white solid, $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.94 – 7.79 (m, 2H), 7.52 – 7.48 (m, 2H), 7.43 – 7.38 (m, 4H), 7.37 – 7.22 (m, 7H), 2.29 (s, 3H); $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 151.20, 141.41, 140.15, 133.83, 130.69, 130.04, 128.63, 128.43, 128.38, 128.10, 127.85, 127.54, 126.69, 124.69, 114.12, 10.19; **HRMS** (ESI-TOF) m/z Calcd for $\text{C}_{22}\text{H}_{19}\text{N}_2$ $[\text{M}+\text{H}]^+$ 311.1543, found 311.1547.




1,3,4,5-Tetraphenyl-1H-pyrazole: white solid, $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.58 – 7.55 (m, 2H), 7.41 – 7.19 (m, 14H), 7.18 – 7.06 (m, 4H); $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 150.17, 141.33, 139.93, 133.10, 130.67, 130.40, 130.04, 128.72, 128.36, 128.22, 128.15, 128.10, 127.58, 127.17, 126.61, 125.28, 120.67; **HRMS** (ESI-TOF) m/z Calcd for $\text{C}_{27}\text{H}_{21}\text{N}_2$ $[\text{M}+\text{H}]^+$ 373.1699, found 373.1703.




2-Methyl-3-phenyl-2H-indazole¹⁴: colorless oil, ¹H NMR (400 MHz, CDCl₃) δ 7.72 (d, *J* = 8.7 Hz, 1H), 7.59 (d, *J* = 8.7 Hz, 1H), 7.59 – 7.50 (m, 4H), 7.53 – 7.44 (m, 1H), 7.34 – 7.30 (m, 1H), 7.13 – 7.04 (m, 1H), 4.19 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 147.99, 135.96, 129.63, 129.50, 128.93, 128.64, 126.19, 121.73, 121.11, 120.05, 116.92, 38.47.


3. Total Synthesis of Nigellidine




4-Methoxy-3-(4-methoxyphenyl)-6-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole 8: To a 100 mL sealed tube, were added Pd(OAc)₂ (74.8 mg, 0.333 mmol, 0.1 eq), 1,10-phenanthroline (180 mg, 1.0 mmol, 0.3 eq), Cs₂CO₃ (3.25 g, 10 mmol, 3.0 eq), 4-bromoanisole (1.7 mL, 13.32 mmol, 4.0 eq), indazole **7** (820 mg, 3.33 mmol), and toluene (13 mL). The tube was capped and stirred at 160 °C for 72 h. The reaction mixture was cooled to room temperature and diluted with EtOAc, filtered through a short pad of Celite, washed with EtOAc, and concentrated in *vacuo*. The resulting residue was purified by silica gel column using hexanes:EtOAc (6:1) as the eluent to give a white solid, 634 mg (54% yield). ¹H NMR (400 MHz, CDCl₃) δ 7.92 – 7.86 (m, 2H), 7.01 – 6.94 (m, 3H), 6.36 (s, 1H), 5.68 (dd, *J* = 9.5, 2.8 Hz, 1H), 4.13 – 4.02 (m, 1H), 3.87 (s, 6H), 3.82 – 3.70 (m, 1H), 3.70 – 3.60 (m, 1H), 2.50 (s, 3H), 2.24 – 2.13 (m, 1H), 2.12 – 2.02 (m, 1H), 1.84 – 1.59 (m, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 159.24, 153.90, 144.67, 143.31, 138.29, 130.82, 126.66, 113.10, 111.73, 102.60, 102.36, 85.31, 67.45, 55.20, 55.07, 29.23, 25.11, 22.68, 22.30; HRMS (ESI-TOF) *m/z* Calcd for C₂₁H₂₅N₂O₃ [M+H]⁺ 353.1860, found 353.1862.




4-Methoxy-3-(4-methoxyphenyl)-6-methyl-1H-indazole 9: To a solution of compound **8** (0.46 g, 1.3 mmol, 1.0 eq) in MeOH (20 mL), was added AcCl (2.8 mL, 39 mmol, 30 eq) dropwise at 0 °C. The solution was heated to 55 °C for 2 h, then cooled to rt and evaporated in *vacuo*. The residue was diluted with EtOAc, washed with saturated NaHCO₃, and brine, dried over Na₂SO₄, filtered, and evaporated to give nearly pure product, white solid, 304 mg (87% yield). ¹H NMR (400 MHz, CDCl₃) δ 7.95 – 7.86 (m, 2H), 7.05 – 6.97 (m, 2H), 6.46 – 6.37 (m, 1H), 6.30 (s, 1H), 3.89 (s, 3H), 3.87 (s, 3H), 2.39 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 159.41, 153.88, 145.59, 144.17, 138.42, 130.94, 126.74, 113.38, 110.41, 102.42, 102.06, 55.25, 55.10, 22.08; HRMS (ESI-TOF) *m/z* Calcd for C₁₆H₁₇N₂O₂ [M+H]⁺ 269.1284, found 269.1285.



1-(4-Bromobutyl)-4-methoxy-3-(4-methoxyphenyl)-6-methyl-1H-indazole 10: To a suspended solution of NaH (60% in mineral oil, 86 mg, 2.14 mmol, 2.0 eq) in DMF (2 mL) and DMSO (1 mL), was added compound **9** (287 mg, 1.07 mmol, 1.0 eq) in DMF (2 mL) at 0 °C under N₂ atmosphere. The mixture was stirred at rt for 20 min, then cooled back to 0 °C, and 1,4-dibromobutane (0.38 mL, 3.21 mmol, 3.0 eq) was added. The resulting mixture was stirred at rt overnight, quenched by saturated NH₄Cl, extracted with EtOAc. The combined organic layers were washed with brine, dried over Na₂SO₄, evaporated in *vacuo*. The residue was purified by silica gel column using hexanes:EtOAc (6:1) as the eluent to give a colorless oil, 321 mg (74% yield). ¹H NMR (400 MHz, CDCl₃) δ 7.88 – 7.79 (m, 2H), 7.01 – 6.93 (m, 2H), 6.76 (s, 1H), 6.32 (s, 1H), 4.36 (t, *J* = 6.8 Hz, 2H), 3.88 (s, 3H), 3.87 (s, 3H), 3.42 (t, *J* = 6.6 Hz, 2H), 2.49 (s, 3H), 2.16 – 2.05 (m, 2H), 1.97 – 1.84 (m, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 159.20, 154.12, 144.12, 143.26, 138.12, 130.65, 126.67, 113.25, 111.00, 101.86, 101.23, 55.26, 55.11, 47.71, 33.15, 29.85, 28.27, 22.36; HRMS (ESI-TOF) *m/z* Calcd for C₂₀H₂₄BrN₂O₂ [M+H]⁺ 403.1016, found 403.1012.



1-Methoxy-11-(4-methoxyphenyl)-3-methyl-6,7,8,9-tetrahydropyridazino[1,2-a]indazol-10-ium Bromide 11: To a 35 mL sealed tube, were added compound **10** (310 mg, 0.77 mmol, 1.0 eq) and acetonitrile (5 mL). The tube was capped and stirred at 110 °C overnight. The reaction mixture was cooled to room temperature and concentrated in *vacuo*. The resulting residue was recrystallized with DCM/Hexane to give a white solid, 250 mg (81% yield). ¹H NMR (400 MHz, CDCl₃) δ 7.73 – 7.60 (m, 2H), 7.11 – 7.02 (m, 2H), 6.98 (s, 1H), 6.45 (s, 1H), 4.77 – 4.61 (m, 4H), 3.88 (s, 3H), 3.75 (s, 3H), 2.52 (s, 3H), 2.52 – 2.47 (m, 2H), 2.37 – 2.24 (m, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 161.58, 154.68, 147.03, 143.21, 142.06, 132.35, 116.52, 113.97, 109.84, 105.65, 101.41, 55.67, 55.40, 48.81, 46.99, 23.05, 20.28, 19.36; HRMS (ESI-TOF) *m/z* Calcd for C₂₀H₂₄BrN₂O₂ [M+H]⁺ 403.1016, found 403.1023.






Nigellidine Hydrobromide 12:¹⁵ To a solution of compound **11** (40.3 mg, 0.1 mmol, 1.0 eq) in DCM (6 mL), was added BBr₃ (1M in DCM, 0.6 mL, 0.6 mmol, 6.0 eq) dropwise at rt. The solution was stirred at rt for 4h, then quenched with slow addition of MeOH (2 mL), and anhydrous K₂CO₃ (1.0 g) with vigorous stirring. The solution was then filtered through a pad of Celite and washed with DCM. The filtrate was concentrated in *vacuo* and the resulting residue was purified by column (DCM/MeOH = 4/1) to give a pale yellow solid, 28 mg (74% yield). The solid was dissolved in hot methanol, then kept in an open flask at room temperature until the crystals were formed. ¹H NMR (400 MHz, DMSO-*d*₆) δ 7.59 – 7.43 (m, 2H), 7.09 (s, 1H), 7.06 – 6.91 (m, 2H), 6.71 – 6.55 (m, 1H), 4.48 (t, *J* = 6.1 Hz, 2H), 4.39 (t, *J* = 5.8 Hz, 2H), 2.44 (s, 3H), 2.23 – 2.17 (m, 2H), 2.12 – 2.07 (m, 2H); ¹³C NMR (151 MHz, DMSO) δ 160.73, 154.48, 146.78, 143.94, 143.23, 133.39, 116.14, 116.10, 109.97, 109.89, 100.53, 49.16, 47.51, 23.24, 20.73, 20.08; HRMS (ESI-TOF) *m/z* Calcd for C₁₈H₁₉N₂O₂ [M-Br]⁺ 295.1441, found 295.1447.


References:



- (1) S. E. Denmark, J. D. Baird, C. S. Regens, *J. Org. Chem.*, 2008, **73**, 1440–1455.
- (2) R. C. Wheeler, E. Baxter, I. B. Campbell, S. J. F. MacDonald, *Org. Process Res. Dev.*, 2011, **15**, 565–569.
- (3) Y. Fang, R. Larock, C. Wu, F. Shi, *J. Org. Chem.*, 2011, **76**, 8840–8851.
- (4) A. E. Shumeiko, A. A. Afonkin, N. G. Pazumova, M. L. Kostrikin, *Russ. J. Org. Chem.*, 2006, **42**, 294–295.
- (5) G. Luo, L. Cheng, G. Dubowchik, *J. Org. Chem.*, 2006, **71**, 5392–5395.
- (6) S. Yu, A. Haight, B. Kotecki, L. Wang, K. Lukin, D. R. Hill, *J. Org. Chem.*, 2009, **74**, 9539–9542.


- (7) D. J. Slade, N. F. Pelz, W. Bodnar, J. W. Lampe, P. S. Watson, *J. Org. Chem.*, 2009, **74**, 6331–6334.
- (8) R. SanMartin, E. Martinez de Marigorta, E. Dominguez, *Tetrahedron*, 1994, **50**, 2255–2264.
- (9) R. Olivera, R. SanMartin, E. Dominguez, *J. Org. Chem.*, 2000, **65**, 7010–7019.
- (10) J. de Mendoza, P. Prados, J. Elguero, *Heterocycles*, 1985, **23**, 2629–2634.
- (11) I. Adachi, *Chem. Pharm. Bull.*, 1969, **17**, 2209–2216.
- (12) S. Perunheralathan, T. A. Khan, H. Ila, H. Junjappa, *J. Org. Chem.*, 2005, **70**, 10030–10035.
- (13) N. A. Markina, A. V. Dubrovskiy, R. C. Larock, *Org. Biomol. Chem.*, 2012, **10**, 2409–2412.
- (14) S. A. Ohnmacht, M. F. Greaney, A. J. Culshaw, *Org. Lett.*, 2010, **12**, 224–226.
- (15) E. L. Elliott, S. M. Bushell, M. Cavero, B. Tolan, T. R. Kelly, *Org. Lett.*, 2005, **7**, 2449–2451.






























































Current Data Parameters
NAME NGH1_2012_10_12
EXPCNO 10
PROCNO 1

F2 - Acquisition Parameters
Date_ 20121012
Time 15.47
INSTRUM spect
PROBHD 5 mm PABBO BB
PULPROG zg30
TD 65536
SOLVENT CDCl3
NS 16
DS 2
SWH 12019.230 Hz
FIDRES 0.183399 Hz
AQ 2.7263477 sec
RG 203
DM 41.600 usec
DE 10.18 usec
TE 300.0 K
D1 1.0000000 sec
TD0 1

CHANNEL f1
NUC1 1H
P1 13.30 usec
P1M1 16.0000000 W
SFO1 400.1918309 MHz

F2 - Processing parameters
SI 32768
SF 400.1900000 MHz
KHZ 0
SSB 0
LB 0.30 Hz
GB 0
PC 1.00



1y




Current Data Parameters
NAME: MM1_2012_11_09
EXPNO: 25
PROCNO: 1

F2 - Acquisition Parameters
Date_ 20121109
Time 22.41
INSTRUM spect
PULPROG 5 mm PASSPO SR/
PC sptpr0
TD 65536
SOLVENT CDCl3
NS 800
DS 4
SWH 32467.512 Hz
FIDRES 0.495415 Hz
AQ 1.0093044 sec
RG 203
SW 15.400 umsec
SE 6.50 umsec
TE 300.2 K
D1 2.5000000 sec
D11 0.0000000 sec
TSD 1

----- CHANNEL f1 -----
NUC1 13C
P1 16.00 umsec
PL1 48.0000000 W
SFO1 100.6404226 MHz
----- CHANNEL f2 -----
CPDPRG2 waltz164
NUC2 1H
PCPD2 96.00 umsec
PL2 12.0000000 W
PL12 0.2700000 W
PL13 0.2187000 W
SFO2 400.1314000 MHz



F2 - Processing parameters
SI 32768
SF 100.6270000 MHz
WDW EM
SSB 0
LB 1.00 Hz
GB 0
PC 1.40






7.51
7.51
7.50
7.50
7.49
7.49
7.48
7.47
7.46
7.45
7.43
7.43
7.42
7.41
7.32
7.32
7.31
7.30
7.30
7.29
7.28
7.28
7.26



2.74
2.74
2.73
2.72
2.71
2.61
2.60
2.59
2.59
2.58
1.82
1.81
1.80
1.79
1.79
1.78
1.77
1.77


0.01



























































































































































































S-90














Current Data Parameters
NAME NSM1_2012_10_11
EXPNO 10
PROCNO 1

F2 - Acquisition Parameters
Date_ 20121011
Time 13.52
INSTRUM spect
PROBHD 5 mm PABBO BB/
PULPROG zg30
TD 65534
SOLVENT CDCl3
NS 16
DS 2
SWH 12019.230 Hz
FIDRES 0.183399 Hz
AQ 2.7243477 sec
RG 203
EM 41.600 usec
DE 10.18 usec
TE 300.0 K
D1 1.00000000 sec
YD0 1

CHANNEL f1
NUC1 1H
P1 13.30 usec
PLM1 16.00000000
SFO1 400.1918309 MHz

F2 - Processing parameters
SI 32768
SF 400.1900000 MHz
MEM 8M
SSB 0
LB 0.30 Hz
CB 0
PC 1.00



2y




Current Data Parameters
NAME: NMR_2012_10_22
EXPNO: 1
PROCNO: 1

F1 - Acquisition Parameters
Date_ 20121024
Time 2.09
INSTRUM spect
PROBHD 5 mm PABBO BB-
PULPROG zgpg30
TD 65536
SOLVENT CDCl3
NS 800
DS 4
SWH 32467.523 Hz
FIDRES 0.495413 Hz
AQ 1.002044 sec
RG 200.52
EW 15.400 usec
DR 6.50 usec
TR 301.5 K
CL 2.5000000 sec
D11 0.0000000 sec
TD 1


----- CHANNEL f1 -----
NUC1 13C
P1 8.50 usec
P1M1 62.0000000 W
SFO1 100.6253442 MHz



----- CHANNEL f2 -----
CPDPRG2 waltz16
NUC2 1H
P2 90.00 usec
P2M2 15.80000013 W
P2M12 0.30000000 W
P2M13 0.32000000 W
SFO2 400.1314005 MHz


F2 - Processing parameters
SI 32768
SF 100.6127690 MHz
WDW EM
SSB 0
LB 1.00 Hz
GB 0
PC 1.40





2y









7.56
7.57
7.55
7.58
7.37
7.36
7.35
7.34
7.33
7.33
7.32
7.31
7.30
7.29
7.28
7.27
7.27
7.26
7.26
7.25
7.25
7.24
7.24
7.22
7.22
7.22
7.21
7.21
7.16
7.15
7.14
7.14
7.14
7.13
7.11
7.11
7.10
7.10
7.09
7.09

0.04

